Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing Co's EPS (Basic) for the
three
months ended in Mar. 2026 was €0.02.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.12.
During the past 12 months, Pharmaron Beijing Co's average EPS without NRIGrowth Rate was -13.90% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 2.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 8.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 19.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 12 years, Pharmaron Beijing Co's highest 3-Year average EPS without NRI Growth Rate was 44.40% per year. The lowest was -5.30% per year. And the median was 26.90% per year.
Pharmaron Beijing Co (FRA:17Q1) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Pharmaron Beijing Co EPS (Diluted) Related Terms
Pharmaron Beijing Co EPS (Diluted) Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:17Q1 vs VRTX, REGN, ALNY: EPS (Diluted) Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Pharmaron Beijing Co's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (FRA:17Q1) has a EPS (Diluted) of €0.12 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's EPS (Diluted) too high?
Pharmaron Beijing Co's current EPS (Diluted) is €0.12. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's EPS (Diluted) compare to VRTX and REGN?
Pharmaron Beijing Co's EPS (Diluted) of €0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current EPS (Diluted) is €0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (FRA:17Q1) has a current EPS (Diluted) of €0.12. The stock's GF Value™ is €2.23, compared to a current price of €2.58 — trading 15.7% above its estimated fair value. The current EPS (Diluted) is €0.12. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Pharmaron Beijing Co (FRA:17Q1), the current EPS (Diluted) is €0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (FRA:17Q1) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of €2.58 is trading 15.7% above its estimated GF Value™ of €2.23.
Key valuation signals for FRA:17Q1:
EPS (Diluted): €0.12
GF Value™: €2.23 vs. price of €2.58 (15.7% above fair value)
No single metric tells the full story. See the FRA:17Q1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for FRA:17Q1
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:17Q1 has been successfully added to your 
